Enveda

Today we are announcing a $311M Series E to bring pharma into the 21st century. Enveda started with a thesis: a molecule that evolution has already refined is a better place to begin than one designed from scratch. This year, two first-in-class molecules discovered by Enveda (ENV-294 and ENV-308) had positive readouts in humans. Many more are behind them. We are grateful to Catalio Capital Management for leading this round, to our new investors Durable Capital Partners, ICONIQ, Lightspeed, Surveyor Capital (a Citadel company), accounts advised by T. Rowe Price, Digitalis Ventures and Alderline Group, and to Baillie Gifford, Premji Invest, True Ventures, Kinnevik AB, FPV Ventures, DIMENSION, Lifeforce Capital and Lux Capital for continuing to back us. The best is yet to come… Read more: #Biotech #AI #LearningfromLife